AllSci News
Servier secures option to Luxna's XNA chemistry platform for neurological ASO programs
Servier has expanded its research collaboration focused on Luxna Biotech Co., Ltd's XNAs Technology platform. The France-based pharmaceutical giant has...
Kali, Sanofi's tri-specific T-cell engager cleared for US study in rheumatoid arthritis
California-based Kali Therapeutics announced US FDA clearance of an investigational new drug (IND) application for KT501, a trispecific B-cell–depleting...
France clears Sensorion's gene therapy SENS-601 into human testing for GJB2 hearing loss
France's drug regulator has cleared Sensorion to begin human testing of SENS-601, its adeno-associated virus (AAV)-based gene therapy for GJB2-related...
Menarini puts up EUR 726M for Euro rights to Gan & Lee’s biweekly GLP-1
China-based Gan & Lee Pharmaceuticals (SSE: 603087) has licensed European rights to bofanglutide (GZR18), its biweekly glucagon-like peptide-1 receptor...
NEJM publishes daraxonrasib NSCLC data supporting Phase III program
Revolution Medicines (Nasdaq: RVMD) has published updated Phase I/II data in the New England Journal of Medicine showing antitumor activity for daraxonrasib...
NMPA accepts Hansoh’s B7-H3 ADC HS-20093 in post-platinum SCLC
China's National Medical Products Administration (NMPA) has accepted a biologics license application from Hansoh Pharmaceutical Group Company Limited (HKEX:...
ARPA-H backs Waterfall Scientific-led mRNA manufacturing platform with up to USD 54.5m
Worcester, Massachusetts-based Waterfall Scientific has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to lead a six-company...
Akeso's ivonescimab beats Keytruda on overall survival in advanced NSCLC
Akeso's ivonescimab has now demonstrated a statistically significant overall survival benefit versus Merck's Keytruda (pembrolizumab) monotherapy in...
GSK bets USD 1.3b on HutchMed's KRAS-EGFR conjugate
GSK has agreed to pay USD 110 million upfront for exclusive rights to develop and commercialize HMPL-A830, a pre-clinical antibody-targeted therapy...
Ultragenyx’s Angelman setback puts UBE3A strategy under scrutiny
The Phase III Aspire study of apazunersen (GTX-102) in Angelman syndrome failed to meet its primary endpoint, leaving the condition without an approved...
TScan restructures around in vivo TCR-T, pauses Phase III hematology program
Waltham, Massachusetts-based TScan Therapeutics (Nasdaq: TCRX) announced a major restructuring that will shift the company away from near-term development...
Vincere Bio wins grant for USP30 inhibitor IND-enabling studies in acute kidney injury
Vincere Biosciences, a small molecule drug developer, has received a USD 1.3 million SBIR Phase II grant from the National Institute of Diabetes and...
Boston Children's Hospital picks up USD 3.9m NIH grant to target endometriosis pain via lipid receptors
Boston Children's Hospital has received a USD 3.9 million NIH R01 grant to identify specialized pro-resolving lipid mediator (SPM) receptors as druggable...
GentiBio secures NIH backing for allogeneic engineered Treg therapy in type 1 diabetes
Cambridge, Massachusetts-based GentiBio, Inc. has received a USD 1.07 million NIH R44 SBIR Phase II grant from the National Institute of Diabetes and...
Taveos' unraveling accelerates as UK joins global regulatory retreat
A rare autoimmune vasculitis treatment has lost its UK authorization after regulators concluded that data underpinning its approval can no longer be...
The AllSci Brief
Free, systematic R&D and deal news. Daily.